C12Y 207/01001
Hexokinase
Official title: Hexokinase (2.7.1.1)
C12Y207/01001 (Hexokinase) appears on 36 US grants and 66 published applications in this corpus.
Search patents in C12Y- Granted patents
- 36
- Published applications
- 66
- Assignees
- 48
- Inventors
- 143
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 4 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 2 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 1 | 1 |
| 2011 | 0 | 1 |
| 2012 | 3 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 2 | 3 |
| 2016 | 0 | 3 |
| 2017 | 1 | 3 |
| 2018 | 0 | 2 |
| 2019 | 3 | 9 |
| 2020 | 6 | 6 |
| 2021 | 4 | 3 |
| 2022 | 2 | 7 |
| 2023 | 1 | 1 |
| 2024 | 0 | 5 |
| 2025 | 2 | 7 |
| 2026 | 3 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biological devices and methods of use thereof to produce steviol glycosides28 Jul 2026US 12,692,502 B2Bio Capital Holdings, LLC
- Peptides with anti-tumor activity19 May 2026US 12,629,408 B2Universita' Degli Studi Di Padova
- Hexokinase 1 isoform B for use as a prognosis marker and specific target against cancer17 Mar 2026US 12,578,339 B2
- Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes27 May 2025US 12,311,059 B2Quince Therapeutics S.p.A.
- Glucose responsive insulins4 Feb 2025US 12,214,018 B2Protomer Technologies, Inc.
- Production of molecules by periplasmic enzymatic catalysis7 May 2026US 2026/0125713 A1Bioc3
- Genetically modified yeast and fermentation processes for the production of lactate28 Aug 2025US 2025/0270597 A1Cargill, Incorporated
- Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes14 Aug 2025US 2025/0255826 A1Quince Therapeutics S.p.A.
- Liquid-dispersible halopyruvate formulations and associated methods7 Aug 2025US 2025/0248956 A1
- Glucose responsive insulins7 Aug 2025US 2025/0249074 A1Protomer Technologies, Inc.
Most cited
By later US patents
- Hexokinase inhibitors53US 5,854,067 ABetagene, Inc. · 1998
- 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor42US 7,411,054 B2Millennium Pharmaceuticals, Inc. · 2008
- Engineered cells producing insulin in response to glucose30US 5,427,940 ABoard of Regents, The University of Texas System · 1995
- Devices comprising genetically engineered .beta.cells8US 5,747,325 ABoard of Regents, The University of Texas System · 1998
- Methods of using genetically engineered cells that produce insulin in response to glucose7US 5,993,799 ABoard of Regents, The University of Texas System · 1999